BrainScope’s EEG-Based Biomarker Predicts Dementia Risk Up to 7 Years Before Initial Diagnosis, Published in Nature Scientific Reports
BrainScope, a commercial-stage medical neurotechnology company applying artificial intelligence and computational neuroscience to brain electrical activity (EEG), today announced the publication of a peer-reviewed study in Scientific Reports (Nature Portfolio) demonstrating the ability of its EEG-based biomarker to identify individuals at risk of cognitive decline within five to seven years before cognitive decline to mild cognitive impairment (MCI), a precursor to different forms of dementia, or conversion to Alzheimer’s type dementia.
BrainScope Names Matt Adams as Chief Executive Officer
BrainScope, a leading neurotechnology company that transforms brain health diagnostics through applying computational neuroscience to brain electrical activity, today announced the appointment of Matt Adams as its new Chief Executive Officer. Adams succeeds Laurie Silver, who will assume the role of President, continuing to help guide the company’s strategic direction and growth. Both Adams and Silver will serve on BrainScope’s Board of Directors.
BrainScope Expands Board and Launches Advanced Deep Learning Platform to Enhance Brain Health Insights
BrainScope®, a leader in AI-enabled EEG technology for brain health assessment, today announced the launch of its next-generation deep learning platform. BrainScope developed and has commercialized the first FDA-cleared AI/machine learning medical device in the field of neurology. Building on that foundation in machine learning, BrainScope's new capabilities enhance its ability to deliver fast, objective, and clinically actionable insights across brain health conditions including concussion, stroke, and early Alzheimer's detection.
BrainScope Completes Proof-of-Concept for Groundbreaking Early Alzheimer’s Prediction Biomarker
BrainScope, a leader in brain diagnostics, today announced the successful completion of the proof-of-concept phase for a novel brain activity-based biomarker for the prediction of onset of Alzheimer’s disease at its earliest stage in normal elderly individuals with memory complaints. This breakthrough was supported by an investment from the Alzheimer’s Drug Discovery Foundation (ADDF).
Recent NFL Concussion and Parkinson’s News Brings Attention to the Long-Term Consequences of Head Impacts in Football
In the aftermath of Miami Dolphins quarterback Tua Tagovailoa suffering another alarming concussion, debate has focused on whether he should retire or risk irreversible brain damage from subsequent concussions. This was closely followed by the announcement of NFL Hall of Famer Brett Favre’s diagnosis of Parkinson’s disease, causing growing concern about the long-term impact of repetitive head impacts in contact sports like football. Favre’s diagnosis sheds light on the increasing evidence linking repeated concussions to neurodegenerative diseases.
BrainScope Receives Investment from the Alzheimer’s Drug Discovery Foundation for Alzheimer's Prediction Biomarker
Brain diagnostics innovator BrainScope announced today a new investment from the Alzheimer’s Drug Discovery Foundation (ADDF) in BrainScope’s current Series B equity financing round. This investment supports the ongoing development of a new Artificial Intelligence / Machine Learning derived brain-activity based biomarker to predict future onset of Alzheimer’s. The company is also evaluating whether its trauma related, FDA-cleared brain bleed biomarker might be effective in detecting ARIAs, a serious side effect of the newly FDA approved Alzheimer’s drugs, so that patients might avoid the expensive and time-consuming multiple MRI scans that are currently recommended.
Statement from BrainScope: Tua Tagovailoa’s Injury and Why We Need a More Objective Assessment of Head Injuries Now
The events of the past week have led to significant concern and conversation about Tua Tagovailoa’s health and recovery and have highlighted the need for changes to the NFL’s concussion protocols. When a player hits his head and is visibly shaken and potentially even collapses, this is a good indication that there is a disruption to brain function. However, misinterpretation of subjective evaluations and self-reporting of symptoms can and do lead to inaccurate conclusions.
BrainScope Named “Best New Diagnostic Technology Solution” in 2022 MedTech Breakthrough Awards Program
Brain-assessment device innovator BrainScope, today announced that it has been selected as “Best New Diagnostic Technology Solution” in the sixth annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global health and medical technology markets.
Prominent Emergency Medicine Expert Diku Mandavia, MD Joins BrainScope as Chief Medical Officer
Brain injury-assessment device innovator BrainScope announced today that Diku Mandavia, MD, has joined the company as Chief Medical Officer. With 28 years of emergency medicine experience and 15 years of commercial medical device experience, Dr. Mandavia is an expert in the importance of point-of-care triage in emergency medicine.
